Drugs / JNJ-64140284
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04566926 | Sep 2020 → Apr 2021 | — | Janssen Pharmaceutica N.V., Belgium | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04033458 | Jul → Aug 2019 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03693391 | Oct 2018 → Mar 2019 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03180762 | May → Sep 2017 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64140284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04033458 ↗ |
| Route | Oral | “will be administered as an oral solution” NCT03180762 ↗ |